Praveena Thiagarajan

Cleveland Clinic — United States

Medicine · Health Sciences

13h-index972citations55works0.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(13), Complement system in diseases(5), Liver Disease and Transplantation(4), Blood groups and transfusion(4), Lung Cancer Treatments and Mutations(3)

Publications55 total

Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria
Blood·2025Open Access
Machine learning uncovers invariant evolutionary molecular trajectories in MDS.
Blood·2025Open Access
C-CBL mutations affecting residue 371 confer dismal prognosis in MDS and CMML
Blood·2025Open Access
Germline alterations of hematopoietic growth factor receptors and maladaptive somatic genetic rescue leads to myeloid neoplasia
Blood·2025
Unsupervised clustering of DDX41 mutants informs on the somatic landscape of single germline hits
Blood·2025Open Access
Exploring the spectrum of non-malignant complications in germline DDX41-associated hematologic disorders
Blood·2025Open Access
Autoimmunity against POLR3A and cytopenias in aplastic anemia and other bone marrow failure syndromes
Blood·2025
Global immunopeptidome remodeling favors piga mutant clones in bone marrow failure
Blood·2025
Concurrent clonality of multiple hematopoietic lineages: Implications for pathogenesis and management of cytopenia
Blood·2025Open Access
Sodium-glucose cotransporter-2 inhibitors may modulate complement pathway activation in paroxysmal nocturnal hemoglobinuria
Blood·2025Open Access
Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies
Transplantation and Cellular Therapy·2025Open Access
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART I
Leukemia Research·2025
POSTER: MDS-1221 Clinically Relevant Effects of GLP-1 Agonists in MDS: Unveiling the Therapeutic Benefits Beyond Glycemic Control—A Global Propensity Score-Matched Analysis
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-1048: A Single-Institution Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MDS-1048 A Single-Institution Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-1221: Clinically Relevant Effects of GLP-1 Agonists in MDS: Unveiling the Therapeutic Benefits Beyond Glycemic Control—A Global Propensity Score-Matched Analysis
Clinical Lymphoma Myeloma & Leukemia·2025
Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
Blood·2024Open Access
LGL <i>Versus</i> MGUS: Clonal Immune Pathogenetic Culprits in Hyporegenerative Anemias and Red Cell Aplasia
Blood·2024Open Access
A Real-Life Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
Blood·2024
An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
Blood·2024Open Access
page 1 of 3Next →

Frequent Co-authors

Carlos Bravo‐Pérez(19), Carmelo Gurnari(19), Mark Orland(18), Valeria Visconte(18), Jaroslaw P. Maciejewski(18), Justin D. Lathia(17), Matteo D’Addona(16), Arda Durmaz(16), Ofer Reizes(14), Serhan Ünlü(12), Luca Guarnera(12), Awad Jarrar(11), Masahiro Hitomi(10), Caner Saygin(9), Christopher Haddad(9), Erin E. Mulkearns-Hubert(8), James S. Hale(8), Anastasia Chumakova(7), Maksim Sinyuk(7), Huiping Liu(7)